Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis

Authors: Ai-Fang Feng, Zhong-Hui Liu, Shu-Long Zhou, Shi-Yuan Zhao, Yan-Xin Zhu, Huai-Xin Wang

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

The meta-analysis was aimed to evaluate the effects of AMPD1 gene C34T polymorphism on cardiac function indexes, blood pressure and prognosis in patients with cardiovascular diseases (CVD).

Methods

Eligible studies were retrieved through a comprehensive search of electronic databases and manual search. Then the high-quality studies met the rigorous inclusion and exclusion criteria, as well as related to the subject was selected for the study. Comprehensive data analyses were conducted using STATA software 12.0.

Results

The study results revealed that CVD patients with CT + TT genotype of AMPD1 C34T polymorphism presented elevated left ventricular ejection fraction (LVEF) (%) and reduced left ventricular end diastolic dimension (LVEDD) (mm) as compared with CC genotype, moreover, the subgroup analysis found that the LVEF (%) was markedly higher in heart failure (HF) patients carrying CT + TT genotype than CC genotype. Besides, the systolic blood pressure (SBP) (mmHg) in CVD patients with CT + TT genotype was obviously decreased in contrast with the CC genotype. Patients suffered from HF with different genotypes (CT + TT and CC) of AMPD1 C34T polymorphism exhibited no significant differences in total survival rate and cardiac survival rate.

Conclusions

Our current meta-analysis indicated that the T allele of AMPD1 gene C34T polymorphism may be correlated with LVEF, LVEDD and SBP, which plays a protective role in the cardiac functions and blood pressure in CVD patients, but had no effects on total survival rate and cardiac survival rate for HF.
Literature
1.
2.
Cooney M, Cooney MT, Maher V, Khan B, Leong T, Graham I. Improvement in the estimation of cardiovascular risk by carotid intima-medial thickness: a report from the Dublin Cardiohealth station study. Prev Med Rep. 2015;2:725–9.CrossRefPubMedPubMedCentral
3.
Ding S, Huang H, Xu Y, Zhu H, Zhong C. MiR-222 in cardiovascular diseases: physiology and pathology. Biomed Res Int. 2017;2017:4962426.PubMedPubMedCentral
4.
Xu S, Jiayong Z, Li B, Zhu H, Chang H, Shi W, et al. Prevalence and clustering of cardiovascular disease risk factors among Tibetan adults in China: a population-based study. PLoS One. 2015;10(6):e0129966.
5.
Perretta-Tejedor N, Fernandez-Mateos J, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Agudo-Conde C, et al. Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors. Sci Rep. 2017;7:41875.
6.
7.
Sharma S, Garg I, Ashraf MZ. TLR signalling and association of TLR polymorphism with cardiovascular diseases. Vasc Pharmacol. 2016;87:30–7.CrossRef
8.
Xuan Y, Wang L, Zhi H, Li X, Wei P. Association between 3 IL-10 Gene polymorphisms and cardiovascular disease risk: systematic review with meta-analysis and trial sequential analysis. Medicine. 2016;95(6):e2846.CrossRefPubMedPubMedCentral
9.
Wang L, Mo X, Xu Y, Zuo B, Lei M, Li F, Jiang S, Deng C, Xiong Y: Molecular characterization and expression patterns of AMP deaminase1 (AMPD1) in porcine skeletal muscle. Comp Biochem Physiol B, Biochem Mol Biol 2008, 151(2):159-166.
10.
Tousoulis D, Kioufis S, Siasos G, Oikonomou E, Zaromitidou M, Maniatis K, et al. The impact of AMPD1 gene polymorphism on vascular function and inflammation in patients with coronary artery disease. Int J Cardiol. 2014;172(3):e516–8.
11.
Sabina RL, Morisaki T, Clarke P, Eddy R, Shows TB, Morton CC, et al. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem. 1990;265(16):9423–33.
12.
Fischer S, Drenckhahn C, Wolf C, Eschrich K, Kellermann S, Froster UG, et al. Clinical significance and neuropathology of primary MADD in C34-T and G468-T mutations of the AMPD1 gene. Clin Neuropathol. 2005;24(2):77–85.
13.
Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 1999;99(11):1422–5.CrossRefPubMed
14.
Collins RP, Palmer BR, Pilbrow AP, Frampton CM, Troughton RW, Yandle TG, et al. Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J. 2006;152(2):312–20.
15.
de Groote P, Lamblin N, Helbecque N, Mouquet F, Hermant X, Amouyel P, et al. The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients. Am Heart J. 2006;152(4):736–41.
16.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMed
17.
18.
19.
Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.CrossRefPubMed
20.
21.
Safranow K, Czyzycka E, Binczak-Kuleta A, Rzeuski R, Skowronek J, Wojtarowicz A, et al. Association of C34T AMPD1 gene polymorphism with features of metabolic syndrome in patients with coronary artery disease or heart failure. Scand J Clin Lab Invest. 2009;69(1):102–12.
22.
Agewall S, Norman B. Association between AMPD1 gene polymorphism and coagulation factors in patients with coronary heart disease. Pathophysiol Haemost Thromb. 2006;35(6):440–4.CrossRefPubMed
23.
Kolek MJ, Carlquist JF, Thaneemit-Chen S, Lazzeroni LC, Whiting BM, Horne BD, et al. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail. 2005;11(9):677–83.
24.
Gastmann A, Sigusch HH, Henke A, Reinhardt D, Surber R, Gastmann O, et al. Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). Am J Cardiol. 2004;93(10):1260–4.
25.
Hoke U, Thijssen J, van Bommel RJ, van Erven L, van der Velde ET, Holman ER, et al. Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy. Diabetes Care. 2013;36(4):985–91.
26.
Bak SH, Ko SM, Jeon HJ, Yang HS, Hwang HK, Song MG. Assessment of global left ventricular function with dual-source computed tomography in patients with valvular heart disease. Acta Radiol. 2012;53(3):270–7.CrossRefPubMed
27.
Breathett K, Allen LA, Udelson J, Davis G, Bristow M. Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction. Circulation Heart failure. 2016;9(10):e002962.
28.
Olsson DP, Eck Arvstrand C, Sartipy U, Holzmann MJ. Acute kidney injury after valvular heart surgery and early changes in cardiac function and structure. Cardiorenal Med. 2014;4(3–4):201–9.CrossRefPubMedPubMedCentral
29.
Yeh JK, Hsiao YC, Jian CR, Wang CH, Wen MS, Kuo CT, et al. Comparison of baseline versus Posttreatment left ventricular ejection fraction in patients with acute Decompensated heart failure for predicting cardiovascular outcome: implications from single-center systolic heart failure cohort. PLoS One. 2016;11(1):e0145514.
30.
Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O, Okada K, et al. Long-term stimulation of adenosine A2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation. 2006;114(18):1923–32.
31.
Qian Y, Lin Y, Zhang T, Bai J, Chen F, Zhang Y, et al. The characteristics of impaired fasting glucose associated with obesity and dyslipidaemia in a Chinese population. BMC Public Health. 2010;10:139.
32.
Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol. 2001;533(Pt 3):881–9.CrossRefPubMedPubMedCentral
33.
Andreassi MG, Botto N, Laghi-Pasini F, Manfredi S, Ghelarducci B, Farneti A, et al. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. Int J Cardiol. 2005;101(2):191–5.
34.
Kalsi KK, Yuen AH, Rybakowska IM, Johnson PH, Slominska E, Birks EJ, Kaletha K, Yacoub MH, Smolenski RT: Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation--a potential mechanism of protection in heart failure. Cardiovasc Res 2003, 59(3):678-684.
35.
Norman B, Sabina RL, Jansson E. Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol. 2001;91(1):258–64.PubMed
Metadata
Title
Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis
Authors
Ai-Fang Feng
Zhong-Hui Liu
Shu-Long Zhou
Shi-Yuan Zhao
Yan-Xin Zhu
Huai-Xin Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0608-0

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue

Research article

Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension

Research article

Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention

Research article

Double product reflects the association of heart rate with MACEs in acute coronary syndrome patients treated with percutaneous coronary intervention

Research article

Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban

Research article

2-Dimensional Speckle Tracking Echocardiography predicts severe coronary artery disease in women with normal left ventricular function: a case-control study

Case report

Successful percutaneous coronary intervention for an in-stent chronic total occlusion in a patient with dextrocardia: a case report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits